| Identification | More | [Name]
Orphenadrine citrate | [CAS]
4682-36-4 | [Synonyms]
beta-dimethylaminoethyl 2-methylbenzhydryl ether citrate
BETA-DIMETHYLAMINOETHYL 2-METHYLBENZHYDRYL ETHER CITRATE SALT
o-methyldiphenhydramine citrate
ORPHENADRINE CITRATE
ORPHENADRINE CITRATE SALT
orphenadrine dihydrogen citrate
Banflex
N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine Citrate Salt
Norflex
X-Ota
β-dimethylaminoethyl 2-methylbenzhydryl ether hydrochloride
ORPHENADRINECITRATE,USP
Orphenadrine citrate
X-Otag | [EINECS(EC#)]
225-137-5 | [Molecular Formula]
C24H31NO8 | [MDL Number]
MFCD00079197 | [Molecular Weight]
461.5 | [MOL File]
4682-36-4.mol |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
132-1340C | [storage temp. ]
2-8°C
| [solubility ]
Sparingly soluble in water, slightly soluble in ethanol (96 per cent). | [form ]
neat | [color ]
White to Pale Beige | [Usage]
Muscle relaxant (skeletal); antihistaminic | [InChIKey]
ASDBZPGDZBFZAH-UHFFFAOYSA-N | [CAS DataBase Reference]
4682-36-4(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn,Xi | [Risk Statements ]
R22:Harmful if swallowed.
R40:Limited evidence of a carcinogenic effect. | [Safety Statements ]
S22:Do not breathe dust .
S36:Wear suitable protective clothing . | [RIDADR ]
3249 | [WGK Germany ]
3
| [HazardClass ]
6.1(b) | [PackingGroup ]
III | [HS Code ]
2922190900 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Originator]
Norflex,Riker,US,1959 | [Uses]
A histaminergic compound | [Uses]
Muscle relaxant (skeletal); antihistaminic | [Uses]
skeletal muscle relaxant, antihistaminic agent | [Definition]
ChEBI: A citrate salt which comprises equimolar amounts of orphenadrine and citric acid. | [Manufacturing Process]
As described in US Patent 2,567,351, o-methylbenzhydryl bromide is added slowly to β-dimethylaminoethanol at refluxing temperature. After the addition has been completed the mixture is refluxed and stirred for an additional 16 hours. The mixture is cooled and the bottom layer consisting of the crude hydrobromide salt of β-dimethylaminoethanol is drawn off. The excess amino alcohol is distilled from the upper layer in vacuo and the residue is reacted with citric acid.
| [Brand name]
Norflex (3M Pharmaceuticals). | [Therapeutic Function]
Muscle relaxant | [General Description]
Orphenadrine citrate, N,Ndimethyl-2-(o-methyl-α-phenylbenzyloxy)ethylamine citrate(1:1) (Norflex), introduced in 1957, is closely related todiphenhydramine structurally but has much lower antihistaminicactivity and much higher anticholinergic action.Likewise, it lacks the sedative effects characteristic ofdiphenhydramine. Pharmacological testing indicates that itis not primarily a peripherally acting anticholinergic becauseit has only weak effects on smooth muscle, on the eye,and on secretory glands. It does reduce voluntary musclespasm, however, by a central inhibitory action on cerebralmotor areas, a central effect similar to that of atropine. | [Clinical Use]
Orphenadrine citrate is used for the symptomatic treatment ofParkinson disease. It relieves rigidity better than it doestremor, and in certain cases, it may accentuate the latter. Thedrug combats mental sluggishness, akinesia, adynamia, andlack of mobility, but this effect seems to diminish rather rapidlywith prolonged use. It is best used as an adjunct to theother agents, such as benztropine, procyclidine, cycrimine,and trihexyphenidyl, in the treatment of paralysis agitans.Orphenadrine citrate is also used as an adjunct to rest, physiotherapy,and other measures to relieve pain of local musclespasm (e.g., nocturnal leg cramps).
The drug has a low incidence of the usual side effectsfor this group, namely, dryness of mouth, nausea, and mildexcitation. | [storage]
Store at -20°C |
|
|